Progress in Early Cancer Diagnosis; Breast Cancer in Younger Women; Diet and Cancer

[MEDPAGE TODAY]( Oncology Update Friday, February 02, 2024 [Progress in Early Cancer Diagnosis; Breast Cancer in Younger Women; Diet and Cancer]( [Sequential Therapy Boosts Survival in Metastatic Pancreatic Cancer]( [Improved Fitness May Reduce Prostate Cancer Risk]( [Most Immunocompromised Patients Clear Omicron Infections]( ['We Caught It Early': Blessing or Burden?]( ADVERTISEMENT Exclusives & Features [Medics Stand Ready to Aid Groundhog Day Crowds]( [What Is Tianeptine and Why Is It in Demand?]( [Cedars-Sinai Anesthesiologists Unionize]( [Acute hospitalizations after proton therapy versus intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in the durvalumab era.]( INTRODUCTION: It was hypothesized that use of proton beam therapy (PBT) in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiation and consolidative immune... [READ MORE]( [Regulatory T cells suppress myeloma-specific immunity during autologous stem cell mobilization and transplantation.]( Autologous stem cell transplantation (ASCT) is the standard of care consolidation therapy for eligible patients with myeloma but most patients eventually progress, an event associated with features... [READ MORE]( [International Anal Neoplasia Society's consensus guidelines for anal cancer screening.]( The International Anal Neoplasia Society (IANS) developed consensus guidelines to inform anal cancer screening use among various high-risk groups. Anal cancer incidence estimates by age among risk... [READ MORE]( [Cerebrospinal fluid cfDNA sequencing for classification of central nervous system glioma.]( PURPOSE: Primary central nervous system (CNS) gliomas can be classified by characteristic genetic alterations. In addition to solid tissue obtained via surgery or biopsy, cell-free DNA (cfDNA) from... [READ MORE]( [Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors.]( PURPOSE: Progression-free survival (PFS) was significantly improved with nivolumab 480 mg plus relatlimab 160 mg fixed-dose combination (FDC) every 4 weeks (Q4W) vs nivolumab alone in patients with... [READ MORE]( [A Property of Everyday Health group]( © 2024 MedPage Today, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=NL_Spec_Oncology_Update?xid=nl_mpt_Oncology_update_2024-02-02&mh=3c4cdd242849aa0e970f25e401732f81) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 114 5th Avenue, 15th Floor New York, NY 10011